GUERBET : Change in Guerbet’s Board of Directors.

Core Viewpoint - Guerbet has appointed Mr. Antoine Fady as a non-voting director, with plans for him to become Chairman, succeeding Mr. Hugues Lecat, who is stepping down for personal reasons [2][3][4]. Group 1: Appointment Details - Mr. Antoine Fady's appointment will be submitted for approval at the next Shareholders' Meeting, with the intention of him becoming Chairman after the meeting [3]. - The Board expressed confidence in Mr. Fady's experience in leading large industrial companies and his strategic vision, which are expected to support Guerbet's transformation and future achievements [4]. Group 2: Mr. Antoine Fady's Background - Mr. Fady is a trained engineer with an MBA from INSEAD and has over ten years of experience as CEO of Flint Group, where he led significant strategic transformations [6]. - He has held various general management roles at ICI and Akzo Nobel, particularly in the paints and coatings sectors in Europe, and has governance experience as a non-executive director and board chairman at Roquette and XSYS [7][8]. Group 3: Company Overview - Guerbet is a global leader in medical imaging, offering a range of pharmaceutical products, medical devices, and digital solutions, with a focus on innovation and R&D, dedicating 10.3% of its revenue to these efforts [10]. - The company achieved €786 million in revenue in 2025 and has a workforce of 2,746 employees worldwide [10].